Introduction
The 2016 European Society of Cardiology heart failure (HF) guidelines 1 recognized HF with mid-range ejection fraction [HFmrEF, ejection fraction (EF) 40-49%] as an entity distinct from HF with reduced EF (HFrEF, EF <40%) and preserved EF (HFpEF, EF ≥50%), calling for studies to address large knowledge gaps regarding epidemiology, aetiology, characteristics, prognosis and treatment in HFmrEF. Data describing the distinguishing clinical characteristics and clinical outcomes in HFmrEF are currently emerging from various cohorts. 2 -11 An EF 40-49% is not normal or preserved; yet importantly, evidence-based therapeutic options are lacking. However, no single dataset has provided comprehensive population-based data on HFmrEF, encompassing inpatients and outpatients, detailed clinical characteristics and medication usage, as well as short-and long-term outcomes. Such comprehensive knowledge is critical for understanding the disease entity, optimizing patient management, designing clinical trials, and ultimately improving outcomes in patients with HFmrEF. Accordingly, we aimed to determine the distinguishing clinical characteristics, outcomes and potential medication response in HFmrEF, compared with HFrEF and HFpEF, in the large population-based HF cohort of the Swedish Heart Failure Registry (SwedeHF).
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Methods
Study population
SwedeHF is an ongoing nationwide registry founded in 2000. 12 The inclusion criterion is clinician-judged HF. The protocol, registration form and annual reports are available at www.rikssvikt.se. The index date was defined as the date of an outpatient visit or hospital discharge. Patients who died during the index hospitalization were excluded, as were registrations with missing EF. The characteristics of patients who were excluded due to missing EF are shown in the Supplementary material online, Table S1 . For patients with multiple registrations, the first encounter was used (Supplementary material online, Figure S1 ).
The SwedeHF Registry provided the study population and baseline clinical characteristics and medications. Additional baseline co-morbidities were provided by ICD-10 codes in any position obtained from linking to the National Patient Registry managed by the National Board of Health and Welfare (www.sos.se). The positive predictive value for most ICD-10 code diagnoses is 85-95%. 13 All diagnoses were considered if present from 1 January 1997, with the exception of cancer, musculoskeletal disease and psychiatric illness, which were considered active only if present in the last 3 years prior to the index date, as previously described.
14 Baseline socioeconomic variables were obtained from Statistics Sweden (www.scb.se).
Establishment of SwedeHF and this study were approved by a multisite ethics committee and complied with the Declaration of Helsinki. Individual patient consent was not required, but patients were informed of entry into national registries and allowed to opt out.
Ejection fraction categories
In the SwedeHF Registry, EF is reported as <30%, 30-39%, 40-49%, or ≥50%. For this study, we stratified HF patients into three EF groups: reduced EF (HFrEF, EF <40%), mid-range EF (HFmrEF, EF 40-49%), and preserved EF (HFpEF, EF ≥50%). 
Statistical analysis
For baseline characteristics, categorical variables were described as numbers and percentages, and continuous variables as mean with standard deviations, or median with interquartile range if skewed. Differences in characteristics across the three EF groups were compared with chi-square test for categorical variables and analysis of variance (ANOVA) for continuous variables. Baseline characteristics were tabulated for all patients. Subsequently, baseline variables with >10% of observations missing and patients with missing data of the variables in the final multivariable model were excluded from further analyses. For variables such as body mass index and New York Heart Association class that were excluded from further analyses due to missing data, sensitivity analyses demonstrate similar observations with 3-year mortality with or without these variables (Supplementary material online, Table S2 ).
To determine the distinguishing and independent clinical characteristics of HFmrEF, multivariable binary logistic regression analyses were performed, comparing the association between baseline variables and (i) HFmrEF vs. HFpEF, and (ii) HFmrEF vs. HFrEF. Age-and sex-adjusted analyses were first performed using all 40 available baseline characteristics, followed by multivariable analyses including all covariates with univariable P-values <0.10 as well as a priori selected variables forced into the model based on known clinical significance. The 20 variables included in the multivariable logistic regression determining EF groups are reported in Table 1 .
To determine the association between EF group and death, Cox proportional hazards models including 18 variables were used ( Table 1) .
Coronary artery disease (CAD) was defined as history of ischaemic heart disease, percutaneous coronary intervention and/or coronary artery bypass graft surgery. We tested potential interactions between clinical factors (e.g. CAD, drivers of CAD such as diabetes and hypertension, age, sex, anaemia, and atrial fibrillation) and EF groups. Of particular interest was the significant effect of CAD on the association between EF group and death. Given the substantial prevalence of CAD among the EF groups, we computed hazard ratios (HRs) for all-cause mortality for all patients, and then stratified by CAD status in more detail. The models were repeated for the three designated endpoints (30 days, 1 year and 3 years), and checked for the proportional hazards assumption.
The association between medication use and mortality was examined. Proportional hazards assumption was met at 1 year, but violated at 3 years. Hence, we examined the association between medication use and 1-year mortality for the EF groups. Additionally, amongst the patients with and without CAD, three-way interaction effects (including the second order terms) between CAD, EF group and the respective medication were tested.
A two-tailed P-value of ≤0.05 was considered statistically significant. All statistical analyses were performed with Stata/SE v14.0 (Stata Corp., College Station, TX, USA). 
Results
Baseline characteristics
Of 51 060 unique patients, 8281 (16%) had missing EF and were excluded, and 718 died during hospitalization. Of the remaining 42 061 included patients, 56% had HFrEF, 21% had HFmrEF, and 23% had HFpEF (Supplementary material online, Figure 1S ). In the Supplementary material online, Table S1 compares patients included vs. excluded due to missing EF. The latter tended be older, female, received inpatient care, had higher systolic blood pressure and heart rate, were less likely to have CAD, and were also less frequently treated with standard HF therapy. Table 1 shows the baseline characteristics of the study population and, for illustrative and reference purposes, comprehensive baseline characteristics are also shown in Figure 1 
Independent associations between clinical characteristics and heart failure phenotype
Baseline data in Table 1 and Figure 1 are comprehensive but are unadjusted and may be subject to covariance. To assess potential independent associations with EF group, we performed multivariable logistic regressions for determinants of EF group. Most unadjusted observations were confirmed for clinical characteristics and medication use, but several demographic factors were no longer different after adjustment, most likely due to covariance with age (i.e. after adjustment for age and other covariates, the HF phenotypes no longer differed) (Figure 2 CI, confidence interval; EF, ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
Independent association between heart failure phenotype and outcomes
We observed 3180 deaths among HFpEF patients, 2512 deaths among HFmrEF patients, and 6706 deaths among HFrEF patients up to 3 years ( Table 2) . In crude analysis, mortality was worst in HFpEF overall, in HFrEF and HFpEF with CAD, and in HFpEF without CAD (Figure 3) . After multivariable adjustment, all-cause mortality in the overall cohort was numerically but not significantly higher in HFmrEF vs. HFpEF at all time points, and considerably and significantly higher in HFrEF vs. HFpEF (P for interaction <0.001) at all time points (Figure 4 , top rows). This was similarly observed among inpatients, although among outpatients all-cause mortality was significantly higher in However, without CAD ( Figure 4 , bottom rows), HFmrEF patients had no increased mortality compared with HFpEF and the increased risk in HFrEF vs. HFpEF was significantly attenuated and significant only for 1-year mortality. As history of ischaemic heart disease was the dominant component of CAD, we found that the presence of ischaemic heart disease also modified the relationship between EF group and mortality. The interaction was not evident in those who have had a percutaneous coronary intervention and/or a coronary artery bypass graft procedure.
Of note, CAD modified the association between beta-blocker use and 1-year mortality in HFmrEF: mortality was reduced in HFmrEF with CAD (HR up to 1 year 0.74, 95% CI 0.59-0.92) but not in HFmrEF without CAD (HR 0.99, 95% CI 0.78-1.26). In HFrEF, beta-blockers were associated with reduced 1-year mortality both with and without CAD. In HFpEF, beta-blockers were associated with reduced 1-year mortality only in the absence of CAD ( Figure 5 ). Additional therapeutic groups of evidence-based therapies in HFrEF and/or CAD [angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs)/statins] were associated with reduced risk in all three EF groups with or without CAD (all P ≤ 0.004), and no interactions with CAD. Figure 3 Kaplan-Meier all-cause mortality up to 3 years: (A) all patients; (B) patients with coronary artery disease (CAD); and (C) patients without CAD. Vertical lines and percentages represent survival rates at 30 days, 1 year and 3 years. HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
Discussion
In this real-world contemporary and well characterized registry-based cohort of patients with HF, HFmrEF accounted for over one-fifth of all patients with HF. HFmrEF was an intermediate phenotype, except notably that CAD was as common in HFmrEF and HFrEF, crude all-cause mortality was lower in HFmrEF and HFrEF, adjusted all-cause mortality was lower in HFmrEF and HFpEF, and CAD portended a higher adjusted risk of death in HFmrEF and HFrEF.
Increasing importance of heart failure with mid-range ejection fraction as a distinct phenotypic entity which there are still large gaps in understanding epidemiology, aetiology, characteristics, prognosis and potential treatment. With an ageing population and increasing prevalence of HF with higher EF, the characterization and potential differences between HFmrEF and HFpEF become critical. Improvements in door-to-balloon time and subsequent management for acute coronary syndromes may portend a relatively greater prevalence of HFmrEF vs. HFrEF.
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This is also consistent with our findings showing the important role of CAD in HFmrEF but not in HFpEF. Indeed, the higher prevalence of and risk with CAD appear to unite HFmrEF and HFrEF. Most HF trials either involved HFrEF (EF <35-40%) alone, or HF with EF ≥40-50%, thus failing to distinguish HFmrEF from HFpEF.
16 -20 Limited trial datasets suggest that chronic stable HFmrEF may resemble HFpEF 8 in terms of out-of-hospital all-cause and cardiovascular death, but may be associated with lower in-hospital outcomes such as in-hospital death compared with HFpEF. 9 The only unselected data in HFmrEF is from Get With Figure 4 Hazard ratios (HRs) for heart failure with mid-range ejection fraction (HFmrEF) vs. heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) vs. HFpEF for all-cause mortality up to 30 days (A), 1 year (B) and 3 years (C) for the overall cohort and for patients with and without coronary artery disease (CAD) separately. CI, confidence interval. * Adjusted for index year, age, gender, heart rate, estimated glomerular filtration rate, systolic blood pressure, diabetes, CAD, atrial fibrillation, valve disease, lung disease, anaemia, use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, beta-blocker, diuretic, statin, registration type, living arrangement, and education.
The Guidelines-HF (GWTG-HF), 2, 9 in which outcomes were limited to the in-hospital setting, and a smaller study from Worcester Massachusetts, 3 in which clinical profiling was not as comprehensive as in our current study. Other HF registries used dichotomous cut-offs, grouping HF into two groups, with EF above or below 50% or 40%, thus combining HFmrEF with either HFpEF or HFrEF. 21, 22 Distinctive features of heart failure with mid-range ejection fraction For other characteristics, our results were broadly consistent with a prior report from GWTG-HF showing intermediate characteristics of patients with HFmrEF. 9 Our patients were somewhat older and had more atrial fibrillation (51% vs. 58% vs. 63%) and anaemia (31% vs. 35%), and these co-morbidities were independently associated with HFmrEF and HFpEF. Aortic stenosis was independently associated with HFmrEF and HFpEF, suggesting a potential contribution to these phenotypes. Diabetes mellitus was similarly common among all three EF groups, but in adjusted analyses it was more associated with HFpEF, particularly in the absence of CAD. Future analyses may be necessary to inform about the mechanistic role through which diabetes mellitus drives the HFpEF phenotype in the absence of CAD.
Figure 5
Differential association between use of relevant medications and 1-year all-cause mortality in patients with heart failure and reduced (HFrEF) (A), mid-range (HFmrEF) (B), or preserved ejection fraction (HFpEF) (C). ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CI, confidence interval; HR, hazard ratio. * Adjusted for index year, age, gender, heart rate, estimated glomerular filtration rate, systolic blood pressure, diabetes, CAD, atrial fibrillation, valve disease, lung disease, anaemia, use of ACEi or ARB, beta-blocker, diuretic, statin, registration type, living arrangement, and education. † Significant three-way interaction between CAD, ejection fraction group and beta-blocker (P for interaction =0.023).
The patterns of medication use in our cohort suggest that HFmrEF may in some cases represent recovered/recovering HFrEF, 23 or be perceived by clinicians as a 'less severe' but still treatable form of HFrEF. The high use of ACEi/ARBs and beta-blockers across all three HF groups, despite current lack of evidence-based guidelines for the treatment of HFmrEF or HFpEF, was notable and higher compared with published data from other cohorts, 2,9 and may in part reflect inclusion of co-morbidities such as CAD, diabetes mellitus and kidney disease, but also raises concerns regarding feasibility of trials with these agents in HFmrEF and HFpEF.
ACEi/ARBs were also independently associated with reduced mortality in all three HF groups, consistent with prior observational studies from SwedeHF. 24 27 In contrast to HFrEF, where beta-blockers were associated with reduced mortality regardless of CAD, in HFmrEF, this was true only in the presence of CAD. This again suggests that HFmrEF patients with CAD are more similar to HFrEF than HFmrEF patients without CAD. Our finding adds onto our previous data 14 where we observed lower all-cause mortality with use of beta-blockers among HFpEF patients, particularly among those without CAD. Although we cannot provide causal explanations behind our current observations, we hypothesize that among HFpEF patients with CAD, the predominant pathophysiology may be ischaemic insults resulting in HF. Unlike HFrEF where beta-blockers have been shown to be beneficial, patients who develop HFpEF after an ischaemic insult may have a lower degree of ischaemic insults such that the beneficial effects of beta-blockers cannot be readily appreciated. A recent study of HFpEF patients who developed HF after acute myocardial infarction showed uncertain benefit from beta-blockers. 28 In contrast, among our patients with HFpEF without CAD, the benefits of beta-blockers may be due to a higher proportion of hypertension in these patients. The resulting left ventricular hypertrophy and fibrosis may contribute to the pathogenesis of HFpEF 29 and hence beta-blockers may have beneficial effects on hypertrophy and fibrosis. However, the role of beta-blockers in HFpEF is still not fully elucidated and requires future research.
Study limitations and strengths
We assessed the associations between baseline characteristics and baseline EF group, but we cannot demonstrate causality. It is reasonable to assume that higher age, hypertension and CAD preceded the HF event and thus affected EF, and it is reasonable to assume that EF determined the choice of therapy. However, it is less clear whether atrial fibrillation was a driver, or a consequence of, or a bystander to the EF phenotype. Analogously, we can only establish associations and not causality between EF group and outcomes. It is also possible that patients with preserved EF were less likely to have been investigated for CAD, thus underestimating the proportion of patients with CAD in the HFpEF group. Future studies on these patients and on ischaemic and non-ischaemic outcomes, as well as the impact of revascularization and longitudinal changes in EF may be useful. We report all-cause mortality but did not have access to cause-specific mortality, although cardiovascular deaths are highly correlated with all-cause mortality in HF patients. 30 The limitation of the 'clinician-judged HF' diagnosis in the SwedeHF Registry is also acknowledged. There is no specific validation study to ascertain the reliability of HF diagnosis in the SwedeHF, although for patients who have had a hospitalization for HF, their records would have been captured in the Swedish National Inpatient Register (as a component of the National Patient Registry), which have positive predictive values for specific diagnoses in the range of 85-95%. 13 Finally, missing data on EF are of concern, as EF was likely not missing at random and patients with missing EF differed with considerably higher age and potentially a considerably worse prognosis. However, given that EF was the main independent variable in our analyses, we did not consider it appropriate to perform imputation for missing EF and instead excluded those patients, limiting generalizability of the findings.
Overall, the large sample size, extensive clinical, demographic and treatment characteristics, and long-term follow-up lend reliability (internal validity), and the unselective nature of the nationwide registry lends generalizability (external validity) to our findings. However, coverage is not complete, and patients in the registry may differ from those not registered. 
Conclusion
In this large population-based cohort, we provide detailed reference data on the HFmrEF phenotype. This information is useful for understanding the clinical HFmrEF phenotype and for the design of future interventional trials in both HFmrEF and HFpEF, neither of which currently have any evidence-based treatment. Specifically, we show that HFmrEF was overall an intermediate phenotype between HFpEF and HFrEF with the important exception of CAD, which was both more common and associated with higher mortality in HFmrEF and HFrEF compared with HFpEF. These findings implicate CAD as both a risk factor for incident HF with mid-range (and reduced) EF, and greater mortality in prevalent HF with mid-range (and reduced) EF.
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